Press release
Glaucoma Drugs Market Size 2034 | Allergan, Sun Pharma Advanced Research Company Limited, Santen Pharmaceutical Co., Ltd., D.Western Therapeutics Institute (DWTI), Kowa Ltd., Alcon
Explore the intricate details of the Glaucoma Market: Uncover drug uptake, treatment dynamics, and epidemiological trends with our comprehensive Glaucoma Market Forecast. Click here to stay ahead in healthcare innovation @ Glaucoma Market Size [https://www.delveinsight.com/sample-request/glaucoma-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Key Takeaways from the Glaucoma Market Report
* The Glaucoma diagnosed prevalent cases were further divided into open-angle glaucoma (OAG) and closed-angle glaucoma. The distribution showed that nearly 90% of glaucoma cases are of OAG type.
* Primary Open-Angle Glaucoma (POAG) and Secondary Open-Angle Glaucoma (SOAG) are two types of Open-angle glaucoma.
* Normal tension glaucoma (NTG) is a subtype of POAG occurring in the presence of normal IOP. As per DelveInsight's estimates, of all POAG cases in the 7MM, 52% were of NTG type.
* Among EU4 and the UK, Germany had the highest diagnosed prevalent population of glaucoma, with 701,946 cases, followed by France in 2022. On the other hand, Spain had the lowest diagnosed prevalent population of glaucoma among EU4 and the UK in 2022.
* Japan accounted for 23% of the total diagnosed prevalent cases of Glaucoma in the 7MM in 2022.
* The leading Glaucoma Companies such as Allergan, Sun Pharma Advanced Research Company Limited, Santen Pharmaceutical Co., Ltd., D.Western Therapeutics Institute (DWTI), Kowa Ltd., Alcon, Senju Pharmaceuticals and Otsuka Pharmaceuticals Co. Ltd., TearClear, Peregrine Ophthalmic, Envisia Therapeutics, Ocuphire Pharma, Sylentis, Nicox Opthalmics, Santen Pharmaceuticals, Perrigo Company, Bausch and Lomb, Ono Pharmaceutical, Novartis, Merck & Co, Aerie Pharmaceuticals, Ube Industries, and others.
* Promising Glaucoma Pipeline Therapies such as NCX-470, PDP-716 (Brimonidine Tartrate Ophthalmic Suspension), TC-002 (latanoprost), iDose TR (Travoprost Intraocular Implant), Sepetaprost/ DE-126/ ONO-9054/ STN-1012600, Catioprost/ DE-130A/ STN1013001, Citicoline eye drops 2%, H-1337, OTX-TIC, LL-BMT1, TRS01, POLAT-001 (Liposomal latanoprost), Nyxol (Phentolamine Mesylate), QLS-101, BTQ-1902, VVN539, and others.
Navigate the complexities of the Glaucoma Market: gain insights into drug trends, treatment scenarios, and epidemiological data through our insightful Glaucoma Market Forecast. Click here to get more insights @ Glaucoma Treatment Market [https://www.delveinsight.com/sample-request/glaucoma-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Glaucoma Epidemiology Segmentation in the 7MM
* Total Glaucoma Prevalence Cases
* Prevalent Cases of Glaucoma by severity
* Glaucoma Gender-specific Prevalence Cases
* Diagnosed Cases of Episodic and Chronic Glaucoma
Delve deep into the Glaucoma Market Landscape: Analyze drug adoption, treatment paradigms, and epidemiological shifts in our detailed Glaucoma Market Forecast. Click here to shape the future @ Glaucoma Prevalence [https://www.delveinsight.com/sample-request/glaucoma-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Glaucoma Market Insights
Glaucoma is an eye disease that gradually steals vision. There are typically no early warning signs or painful symptoms of glaucoma. It develops slowly and sometimes without noticeable sight loss for many years. The damage caused by glaucoma cannot be reversed. But, treatment and regular checkups can help slow or prevent vision loss, especially if the disease is in its early stages. Glaucoma is treated by lowering the eye pressure (intraocular pressure). Depending on the situation, the options may include prescription eye drops, oral medications, laser treatment, surgery, or a combination.
Glaucoma Treatment Market Landscape
Management of the condition revolves around reducing intraocular pressure (IOP) through the use of current drug classes, including prostaglandin analogs, beta-blockers, alpha-agonists, and carbonic anhydrase inhibitors. Despite these treatments, some patients do not experience the desired improvement in their condition. They may still face optic nerve damage even when their IOP levels are within the normal range. In addition to pharmacological treatments, alternatives such as incisional surgery, laser surgery, and medications are also considered.
Glaucoma Drugs Uptake
* NCX 470 is a novel NO-donating bimatoprost eye drop, which is a prostaglandin analog. The drug is currently being developed by Nicox Ophthalmics and is in Phase III of clinical development. It is being developed for the treatment of open-angle glaucoma or ocular hypertension in the US. NCX 470 is designed to release bimatoprost and NO following instillation into the eye.
* PDP-716 is a novel, once-a-day formulation of brimonidine developed using SPARC's TearAct technology for the treatment of glaucoma. The drug provides dosing convenience to patients compared to a currently marketed product that requires thrice-a-day dosing. The drug contains brimonidine, one of the most commonly used treatments for glaucoma and ocular hypertension.
* STN-1012600 is a once-daily prostaglandin eye drop drug product with a novel, dual-mode of action that activates both FP and EP3 receptors (both FP and EP3 receptors are prostaglandin receptors). As it has been reported that both receptors have an effect in reducing intraocular pressure, STN-1012600 is expected to give new therapeutic options for treating glaucoma.
Glaucoma Market Outlook
The report's outlook on the Glaucoma market aids in developing a comprehensive understanding of historical, current, and projected trends. This is achieved by examining the influence of existing Glaucoma therapies, unmet needs, as well as drivers, barriers, and the demand for advanced technology. This section provides detailed insights into the trends of each marketed Glaucoma drug and late-stage pipeline therapy. It assesses their impact based on various factors such as annual therapy costs, inclusion/exclusion criteria, mechanism of action, compliance rates, market demand, patient population growth, covered patient segments, anticipated launch year, competition with other therapies, brand value, and input from key opinion leaders. The analyzed Glaucoma market data are presented concisely through relevant tables and graphs to offer a clear overview of the market dynamics.
Major Glaucoma Companies
Several Glaucoma Companies working in the market include Allergan, Sun Pharma Advanced Research Company Limited, Santen Pharmaceutical Co., Ltd., D.Western Therapeutics Institute (DWTI), Kowa Ltd., Alcon, Senju Pharmaceuticals and Otsuka Pharmaceuticals Co. Ltd., TearClear, Peregrine Ophthalmic, Envisia Therapeutics, Ocuphire Pharma, Sylentis, Nicox Opthalmics, Santen Pharmaceuticals, Perrigo Company, Bausch and Lomb, Ono Pharmaceutical, Novartis, Merck & Co, Aerie Pharmaceuticals, Ube Industries , and others.
Unlock insights into the Glaucoma Market: discover drug uptake patterns, treatment landscapes, and epidemiological insights with our exclusive Glaucoma Market Forecast. Click here @ Glaucoma Market Drivers and Barriers [https://www.delveinsight.com/sample-request/glaucoma-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Scope of the Glaucoma Market Research Report
* Coverage- 7MM
* Glaucoma Companies- Allergan, Sun Pharma Advanced Research Company Limited, Santen Pharmaceutical Co., Ltd., D.Western Therapeutics Institute (DWTI), Kowa Ltd., Alcon, Senju Pharmaceuticals and Otsuka Pharmaceuticals Co. Ltd., TearClear, Peregrine Ophthalmic, Envisia Therapeutics, Ocuphire Pharma, Sylentis, Nicox Opthalmics, Santen Pharmaceuticals, Perrigo Company, Bausch and Lomb, Ono Pharmaceutical, Novartis, Merck & Co, Aerie Pharmaceuticals, Ube Industries, and others.
* Glaucoma Therapies- NCX-470, PDP-716 (Brimonidine Tartrate Ophthalmic Suspension), TC-002 (latanoprost), iDose TR (Travoprost Intraocular Implant), Sepetaprost/ DE-126/ ONO-9054/ STN-1012600, Catioprost/ DE-130A/ STN1013001, Citicoline eye drops 2%, H-1337, OTX-TIC, LL-BMT1, TRS01, POLAT-001 (Liposomal latanoprost), Nyxol (Phentolamine Mesylate), QLS-101, BTQ-1902, VVN539, and others.
* Glaucoma Market Dynamics: Glaucoma Market Drivers and Barriers
* Glaucoma Market Access and Reimbursement, Unmet Needs and Future Perspectives
Gain a strategic edge in the Glaucoma Market: explore comprehensive drug insights, treatment updates, and epidemiological forecasts in our in-depth Glaucoma Market Forecast. Click here to lead in advancements @ Glaucoma Clinical Trials Assessment [https://www.delveinsight.com/sample-request/glaucoma-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Table of Content
1. Key Insights
2. Report Introduction
3. Country-wise Glaucoma Market Overview at a Glance
4. Glaucoma Market Overview by Class
5. Methodology of Glaucoma Epidemiology and Market
6. Executive Summary of Glaucoma
7. Key Events
8. Disease Background and Overview of Glaucoma
9. Epidemiology and Patient Population
10. Patient Journey
11. Glaucoma Marketed Therapies
12. Glaucoma Emerging Therapies
13. Glaucoma Market Analysis
14. Key Opinion Leaders' Views
15. Glaucoma SWOT Analysis
16. Glaucoma Unmet needs
17. Glaucoma Market Access and Reimbursement
18. Appendix
19. Report Methodology
20. DelveInsight Capabilities
21. Disclaimer
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=glaucoma-drugs-market-size-2034-allergan-sun-pharma-advanced-research-company-limited-santen-pharmaceutical-co-ltd-dwestern-therapeutics-institute-dwti-kowa-ltd-alcon]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Glaucoma Drugs Market Size 2034 | Allergan, Sun Pharma Advanced Research Company Limited, Santen Pharmaceutical Co., Ltd., D.Western Therapeutics Institute (DWTI), Kowa Ltd., Alcon here
News-ID: 3607854 • Views: …
More Releases from ABNewswire
Asia Pacific Medical Clothing Market to reach US$ 4.7 Bn in 2032, driven by inno …
The Asia Pacific medical clothing market was valued at US$ 2.6 Billion in 2023 and is expected to register a CAGR of 6.7% over the forecast period and reach US$ 4.7 Billion in 2032.
According to the latest report by Reports and Insights, titled, "Asia Pacific Medical Clothing Market Report: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast" the global Asia Pacificmedical clothing market was valued at USD 2.6 billion…
Apex Roofing Pros Emerges as Leading Roofing Company with Innovative Solutions
By embracing advanced technology and a customer-centric approach, Apex Roofing Pros has set new standards in the industry, offering solutions that cater to the evolving needs of its clientele.
In the dynamic world of home improvement, Apex Roofing Pros has quickly distinguished itself as a leader among roofing companies, thanks to its commitment to innovation and excellence. The company's reputation for delivering top-notch roofing solutions has made it a preferred choice…
Xtreme Fence Expands Reach as the Go-To Fencing Company for Modern Homes
Xtreme Fence, a leading fencing company, is meeting this demand head-on by expanding its reach and solidifying its position as the go-to fencing provider for modern homes and commercial properties alike.
In the rapidly growing world of residential and commercial property development, the demand for high-quality, durable, and aesthetically pleasing fencing solutions has never been more pronounced. As homeowners and business owners alike seek to enhance the security, privacy, and curb…
North American Roofing Marks 45 Years of Superior Commercial Roofing in Tampa
Celebrating Decades of Commitment to Quality and Client Satisfaction in Commercial Roofing
TAMPA, FL - North American Roofing, a leader in the commercial and industrial roofing sector, proudly celebrates its 45th anniversary this year. Since its establishment in 1979, the company has been a pillar of reliability and innovation in the industry. With a reputation for superior quality and service, North American Roofing has consistently delivered exceptional service and cutting-edge solutions…
More Releases for Glaucoma
Micro-Invasive Glaucoma Implants Micro-Invasive Glaucoma Implants
Global Micro-Invasive Glaucoma Implants Market Definition: Micro-invasive glaucoma implants is performed for the treatment of the open- angle glaucoma and is done through an ab- interno approach. It is very safe and provides faster recovery as compared to the traditional methods. They usually lower the intraocular by increasing the flow or reducing the production of the aqueous humor. Increasing cases of the glaucoma worldwide is the major factor fueling the…
Glaucoma – Epidemiology Insights (2016-2028)
Glaucoma can be described as a group of diseases characterized by cupping of the optic nerve head and visual-field damage. These diseases differ from each other in terms of their causes, risk factors, demographics, symptoms, duration, treatment, and prognosis.
Download the sample report @ https://www.pharmaproff.com/request-sample/1159
The common identifiable features for all forms of glaucoma are loss of retinal ganglion cells, thinning of the retinal nerve fiber layer, and cupping of the…
Market Spotlight: Glaucoma
Boston, MA
ReportsWorldwide has announced the addition of a new report title Market Spotlight: Glaucoma to its growing collection of premium market research reports.
Glaucoma is not just one eye disease, but a group of eye conditions resulting in optic nerve damage, which may cause loss of vision and blindness. In glaucoma, damage to the optic nerve is usually caused by elevated intraocular pressure (IOP). IOP rises when passages that allow fluid…
North America Glaucoma Therapeutics Market grows with growing awareness regardin …
Glaucoma Therapeutics Market: Scope and Methodology
The research is a combination of primary and secondary research, conducted for understanding and arriving at trends, used to forecast the expected revenue of the major glaucoma therapeutics market in the near future. Primary research formed the bulk of our research efforts with information collected from in-depth interviews and discussions with a number of key industry experts and opinion leaders. Secondary research involved study…
Glaucoma Treatment Market : Rising Geriatric Population And Healthcare Expenditu …
Glaucoma is a chronic, degenerative, permanent disorder whose rate increases essentially with age rather than causing immediate blindness. According to a survey of WHO, Glaucoma is the second most common cause of blindness affecting the population worldwide after cataract (47.9%). In general, Glaucoma occurs as after effects of increased intraocular pressure (IOP) brought about by an abnormality or malfunctioning of the eye drainage system. The normal IOP is in…
Glaucoma Surgery Devices Market 2016: Glaucoma Systems, Glaucoma Laser Devices
Latest industry research report on Glaucoma surgery devices are used in the glaucoma treating procedure. These procedures include both surgical and laser therapies performed on a patient. The cases of blindness due to glaucoma is on rise across the several countries. Furthermore, the demand for both technologically as well as advanced surgical equipment has resulted in the popularity of glaucoma surgery devices industry, worldwide.
Sudden increase in the aging population and…
